Nurix Therapeutics (NRIX) Return on Capital Employed (2020 - 2026)
Nurix Therapeutics (NRIX) reported Return on Capital Employed of 55.32% for Q1 2026, down 1355.0% year-over-year from 4.41% in Q1 2025, and little changed quarter-over-quarter from 55.06% in Q4 2025.
Nurix Therapeutics (NRIX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 7 years of Return on Capital Employed data on file, last reported at 55.32% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 55.32%, down 1355.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 55.32% (down 1355.0% YoY), and the FY2025 annual result was 48.23%, up 290.0% from the prior year.
- Return on Capital Employed was little changed at 55.32% in Q1 2026 per NRIX's latest filing, from 55.06% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 34.79% in Q1 2022 and troughed at 63.82% in Q1 2024.
- A 5-year average of 51.33% and a median of 54.1% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed slumped 2621 bps in 2022, then soared 2205 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 50.05% in 2022, then fell by 26 bps to 63.31% in 2023, then soared by 32 bps to 42.98% in 2024, then slipped by 28 bps to 55.06% in 2025, then dropped by 0 bps to 55.32% in 2026.
- Business Quant data shows NRIX's Return on Capital Employed at 55.32% in Q1 2026, 55.06% in Q4 2025, and 56.3% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Nurix Therapeutics | 1.93 Bn | 1.39 Bn | - | -55.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -55.32% |
| Nov 30, 2025 | -55.06% |
| Aug 31, 2025 | -56.30% |
| May 31, 2025 | -43.67% |
| Feb 28, 2025 | -41.77% |
| Nov 30, 2024 | -42.98% |
| Aug 31, 2024 | -45.47% |
| May 31, 2024 | -54.10% |
| Feb 29, 2024 | -63.82% |
| Nov 30, 2023 | -63.31% |
| Aug 31, 2023 | -59.13% |
| May 31, 2023 | -57.31% |
| Feb 28, 2023 | -56.02% |
| Nov 30, 2022 | -50.05% |
| Aug 31, 2022 | -48.18% |
| May 31, 2022 | -45.26% |
| Feb 28, 2022 | -34.79% |
| Nov 30, 2021 | -28.16% |
| Aug 31, 2021 | -21.97% |
| May 31, 2021 | -21.96% |